"Metastatic colorectal Cancer" trang 1 - tải miễn phí từ Tailieuchung
Dose escalating study of cetuximab and 5-FU/ folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

Dose escalating study of cetuximab and 5-FU/ folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
8    23    1
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer

Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
14    64    1
A phase Ib study of capecitabine and zivaflibercept followed by a phase II singlearm expansion cohort in chemotherapy refractory metastatic colorectal cancer

A phase Ib study of capecitabine and zivaflibercept followed by a phase II singlearm expansion cohort in chemotherapy refractory metastatic colorectal cancer
9    75    0
Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: A meta-analysis and systematic review

Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: A meta-analysis and systematic review
13    62    1
Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer

Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
10    59    0
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
10    61    1
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
9    38    1
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
10    28    1
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
9    41    1
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
9    8    1
A phase II study of Epirubicin in oxaliplatinresistant patients with metastatic colorectal cancer and TOP2A gene amplification

A phase II study of Epirubicin in oxaliplatinresistant patients with metastatic colorectal cancer and TOP2A gene amplification
5    23    1
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: A retrospective cohort study

Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: A retrospective cohort study
12    8    1
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients

Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
9    30    1
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: Results of a large registry-based cohort analysis

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: Results of a large registry-based cohort analysis
7    27    1
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: Updated results from a phase 3 trial

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: Updated results from a phase 3 trial
7    42    1
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy
9    27    1
Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer

Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer
10    56    1
The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: A retrospective study

The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: A retrospective study
8    30    1
Genomic alterations accompanying tumour evolution in colorectal cancer: Tracking the differences between primary tumours and synchronous liver metastases by wholeexome sequencing

Genomic alterations accompanying tumour evolution in colorectal cancer: Tracking the differences between primary tumours and synchronous liver metastases by wholeexome sequencing
13    34    1
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: A systematic review and meta-analysis

Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: A systematic review and meta-analysis
19    52    1
TAILIEUCHUNG - Chia sẻ tài liệu không giới hạn
Địa chỉ : 444 Hoang Hoa Tham, Hanoi, Viet Nam
Website : tailieuchung.com
Email : tailieuchung20@gmail.com
Tailieuchung.com là thư viện tài liệu trực tuyến, nơi chia sẽ trao đổi hàng triệu tài liệu như luận văn đồ án, sách, giáo trình, đề thi.
Chúng tôi không chịu trách nhiệm liên quan đến các vấn đề bản quyền nội dung tài liệu được thành viên tự nguyện đăng tải lên, nếu phát hiện thấy tài liệu xấu hoặc tài liệu có bản quyền xin hãy email cho chúng tôi.
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.